Shingles Vaccine Market Report 2025

The shingles vaccine market size has grown rapidly in recent years. It will grow from $4.82 billion in 2024 to $5.55 billion in 2025 at a compound annual growth rate (CAGR) of 15%. The growth observed during the historic period can be attributed to the increasing elderly population, rising awareness of vaccine benefits, expansion of healthcare infrastructure and immunization programs, higher incidence of immunocompromised conditions, and growing adoption of newer, more effective vaccines.

The shingles vaccine market size is expected to see rapid growth in the next few years. It will grow to $9.58 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to expanding government reimbursement and favorable pricing policies, increasing physician recommendation rates, rising public health focus on adult vaccination, growing investment in research, development, and product diversification, and improvements in global supply chains and cold-chain capacity. Key trends during this period include advancements in recombinant vaccine technology, innovations in adjuvant systems, integration of shingles vaccination into adult immunization schedules, adoption of digital health platforms for vaccine tracking, and improvements in vaccine formulations.

The growing number of vaccination programs is driving the expansion of the shingles vaccine market. Organized public health initiatives that systematically deliver vaccines increase awareness, accessibility, and adoption, particularly among older adults and high-risk populations. These programs help reduce the incidence of shingles and its complications by promoting timely and widespread immunization, thereby improving overall community health. For example, in July 2025, the World Health Organization reported that global coverage for the first dose of the HPV vaccine in girls rose from 27% in 2023 to 31% in 2024, reflecting increased engagement in preventive vaccination initiatives.

Key players in the shingles vaccine market are focusing on innovative formulations to enhance protection. Recombinant adjuvanted vaccines, for instance, combine lab-produced viral proteins with adjuvants to boost immune response and provide long-lasting protection. In April 2023, GlaxoSmithKline Pharmaceuticals Ltd. launched Shingrix, a non-live, recombinant adjuvanted subunit vaccine administered in two doses for adults aged 50 and above. Shingrix offers over 90% protection against shingles, with immunity lasting at least 10 years, even in older or immunocompromised individuals.

In January 2022, Pfizer Inc. partnered with BioNTech SE to develop an mRNA shingles vaccine. This collaboration aims to leverage mRNA technology to elicit a robust and durable immune response against the varicella-zoster virus, providing a highly effective preventive solution for adults at risk of shingles.

Major players in the shingles vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GSK plc, Daiichi Sankyo Company Limited, Moderna Inc., Novavax Inc., Biological E. Limited., Serum Institute of India Pvt. Ltd., Dynavax Technologies Corporation, SK Bioscience Co. Ltd., CanSino Biologics Inc., Vaxart Inc., EuBiologics Co. Ltd., BCHT Biotech Co. Ltd., Green Cross Corp, Jiangsu Recbio Technology Co. Ltd., Curevo Inc., Inovio Pharmaceuticals Inc., POP Biotechnologies Inc.

North America was the largest region in the shingles vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in shingles vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the shingles vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Shingles vaccine is a preventive immunization designed to protect against shingles (herpes zoster), a painful skin rash caused by the reactivation of the varicella-zoster virus. It stimulates the immune system to recognize and combat the virus, reducing the risk of developing shingles and its associated complications.

The primary types of shingles vaccines include live attenuated vaccines, recombinant vaccines, and subunit vaccines. Live attenuated vaccines use a weakened form of the virus that can replicate without causing disease, eliciting a strong and lasting immune response. Key product types include Shingrix, Zostavax, and Skyzoster, primarily administered to individuals aged 50-59 years, 60-69 years, and 70 years and above. These vaccines are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, serving end users such as hospitals, clinics, and pharmacies.

The shingles vaccine market research report is one of a series of new reports that provides shingles vaccine market statistics, including shingles vaccine industry global market size, regional shares, competitors with a shingles vaccine market share, detailed shingles vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the shingles vaccine industry, This shingles vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The shingles vaccine market consists of sales of vaccine kits, cold chain storage equipment, pre-filled syringes, vaccine delivery devices, and temperature monitoring systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.